Archive: Company News
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
– Compound demonstrates excellent safety and tolerability in single ascending dose trial
– Efficient penetration of blood-brain barrier
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics in neurodegenerative diseases and immuno-oncology, announced a successful completion of its Phase I single ascending dose (SAD) study of FB-101 in healthy adult subjects. FB-101 is a c-Abl inhibitor in development for the treatment of Parkinson’s disease and other neurodegenerative indications associated with the accumulation of alpha-synuclein. The compound was evaluated in a randomized, double-blind, placebo-controlled study to assess its safety, tolerability, and pharmacokinetics.
ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
– Former Novartis director brings significant expertise in drug discovery and development
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).
InfanDx AG Reports Successful Validation of Biomarker Panels for the Early Detection of Hypoxic Ischemic Encephalopathy
— Numerous metabolic biomarkers identified in AAMBI study confirmed in BANON cohort
— Panel sensitivities of up to 89% at specificities of up to 93% in blinded validation study
— Formal IVD development of HypoxE® Test progressing on schedule
InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it successfully completed the validation of metabolic biomarker panels for the early detection of Hypoxic Ischemic Encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the Company’s HypoxE® blood test for the early detection of HIE.
ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
– Seasoned immuno-oncology executive brings significant medical and biopharma expertise
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors.